• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性血栓栓塞性肺动脉高压:治疗评估

Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment.

作者信息

Simeone Beatrice, Maggio Enrico, Schirone Leonardo, Rocco Erica, Sarto Gianmarco, Spadafora Luigi, Bernardi Marco, D'Ambrosio Luca, Forte Maurizio, Vecchio Daniele, Valenti Valentina, Sciarretta Sebastiano, Vizza Carmine Dario

机构信息

Department of Cardiology, ICOT Istituto Marco Pasquali, Latina, Italy.

Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.

出版信息

Front Cardiovasc Med. 2024 Jul 25;11:1439411. doi: 10.3389/fcvm.2024.1439411. eCollection 2024.

DOI:10.3389/fcvm.2024.1439411
PMID:39171327
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11337617/
Abstract

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a severe and complex condition that evolves from unresolved pulmonary embolism, leading to fibrotic obstruction of pulmonary arteries, pulmonary hypertension, and potential right heart failure. The cornerstone of CTEPH management lies in a multifaceted therapeutic approach tailored to individual patient profiles, reflecting the disease's heterogeneity. This review delves into the current therapeutic strategies for CTEPH, including surgical pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and targeted pharmacological treatments such as PDE5 inhibitors, endothelin receptor antagonists, sGC stimulators, and prostanoids. Lifelong anticoagulation is also highlighted as a preventive strategy against recurrent thromboembolism. Special emphasis is placed on the interdisciplinary nature of CTEPH care, necessitating collaboration among PEA surgeons, BPA interventionists, PH specialists, and thoracic radiologists to ensure comprehensive treatment planning and execution. The review underscores the importance of selecting an appropriate treatment modality based on the patient's specific disease characteristics and the evolving landscape of CTEPH treatment, aiming to improve patient outcomes through integrated care strategies.

摘要

慢性血栓栓塞性肺动脉高压(CTEPH)是一种严重且复杂的疾病,由未解决的肺栓塞发展而来,导致肺动脉纤维化阻塞、肺动脉高压以及潜在的右心衰竭。CTEPH管理的基石在于根据个体患者情况定制的多方面治疗方法,这反映了该疾病的异质性。本综述深入探讨了CTEPH的当前治疗策略,包括外科肺动脉内膜剥脱术(PEA)、球囊肺动脉成形术(BPA)以及靶向药物治疗,如磷酸二酯酶5抑制剂、内皮素受体拮抗剂、可溶性鸟苷酸环化酶刺激剂和前列环素类药物。终身抗凝也被强调为预防复发性血栓栓塞的策略。特别强调了CTEPH护理的跨学科性质,需要PEA外科医生、BPA介入专家、肺动脉高压专家和胸科放射科医生之间的合作,以确保全面的治疗计划和实施。该综述强调了根据患者的特定疾病特征和CTEPH治疗的不断发展的情况选择合适治疗方式的重要性,旨在通过综合护理策略改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/a849f36a9fff/fcvm-11-1439411-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/3290d84b903e/fcvm-11-1439411-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/b5f760041fe2/fcvm-11-1439411-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/ceffef344f9e/fcvm-11-1439411-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/a849f36a9fff/fcvm-11-1439411-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/3290d84b903e/fcvm-11-1439411-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/b5f760041fe2/fcvm-11-1439411-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/ceffef344f9e/fcvm-11-1439411-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7d9/11337617/a849f36a9fff/fcvm-11-1439411-g004.jpg

相似文献

1
Chronic Thromboembolic Pulmonary Hypertension: the therapeutic assessment.慢性血栓栓塞性肺动脉高压:治疗评估
Front Cardiovasc Med. 2024 Jul 25;11:1439411. doi: 10.3389/fcvm.2024.1439411. eCollection 2024.
2
[Consensus on the procedure of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension].[慢性血栓栓塞性肺动脉高压球囊肺动脉成形术操作共识]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 May 12;47(5):404-418. doi: 10.3760/cma.j.cn112147-20231231-00403.
3
Chronic thromboembolic pulmonary hypertension: a review of risk factors, management and current challenges.慢性血栓栓塞性肺动脉高压:危险因素、管理及当前挑战综述。
Expert Rev Cardiovasc Ther. 2022 Jan;20(1):35-43. doi: 10.1080/14779072.2022.2034499. Epub 2022 Feb 2.
4
Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.靶向治疗慢性血栓栓塞性肺动脉高压的进展。
Heart Fail Rev. 2019 Nov;24(6):949-965. doi: 10.1007/s10741-019-09798-x.
5
Advances in treatment of chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压的治疗进展
Thromb Res. 2022 Apr;212:30-37. doi: 10.1016/j.thromres.2022.02.003. Epub 2022 Feb 12.
6
Role of Surgical and Medical Management of Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review.慢性血栓栓塞性肺动脉高压的外科及内科治疗作用:一项系统评价
Cureus. 2024 Jan 31;16(1):e53336. doi: 10.7759/cureus.53336. eCollection 2024 Jan.
7
The management pattern and outcomes of chronic thromboembolic pulmonary hypertension: rationale and design for a Chinese real-world study.慢性血栓栓塞性肺动脉高压的管理模式和结局:一项中国真实世界研究的原理和设计。
BMC Pulm Med. 2024 Jun 3;24(1):265. doi: 10.1186/s12890-024-03042-5.
8
Chronic thromboembolic pulmonary hypertension - still evolving.慢性血栓栓塞性肺动脉高压——仍在不断发展。
Glob Cardiol Sci Pract. 2020 Apr 30;2020(1):e202011. doi: 10.21542/gcsp.2020.11.
9
Interventional and pharmacological management of chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压的介入与药物治疗
Respir Med. 2021 Feb;177:106293. doi: 10.1016/j.rmed.2020.106293. Epub 2021 Jan 6.
10
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.球囊肺动脉血管成形术治疗慢性血栓栓塞性肺动脉高压
Cardiovasc Interv Ther. 2020 Apr;35(2):130-141. doi: 10.1007/s12928-019-00637-2. Epub 2019 Dec 23.

引用本文的文献

1
Association of Systemic Inflammatory Response Index with Disease Severity and Adverse Outcome in Chronic Thromboembolic Pulmonary Hypertension.全身炎症反应指数与慢性血栓栓塞性肺动脉高压疾病严重程度及不良预后的相关性
J Inflamm Res. 2025 Jun 21;18:8217-8231. doi: 10.2147/JIR.S517285. eCollection 2025.
2
Pulmonary artery stent thrombosis and symptomatic pulmonary hypertension following COVID-19 infection in Alagille patient: A case report.阿拉吉尔综合征患者感染新冠病毒后出现肺动脉支架血栓形成及症状性肺动脉高压:一例报告
World J Clin Cases. 2025 Mar 26;13(9):96897. doi: 10.12998/wjcc.v13.i9.96897.
3
Meta-Analysis of Real-World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension.

本文引用的文献

1
A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.依度沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验:歌舞伎试验
Circulation. 2024 Jan 30;149(5):406-409. doi: 10.1161/CIRCULATIONAHA.123.067528. Epub 2023 Nov 13.
2
Emerging Role of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease-Insights from the 2022 ESC Guidelines.球囊肺血管成形术在慢性血栓栓塞性肺疾病中的新作用——来自2022年欧洲心脏病学会指南的见解
J Clin Med. 2023 Aug 16;12(16):5336. doi: 10.3390/jcm12165336.
3
评估利奥西呱治疗慢性血栓栓塞性肺动脉高压有效性的真实世界临床实践的Meta分析
J Clin Hypertens (Greenwich). 2025 Feb;27(2):e70015. doi: 10.1111/jch.70015.
4
Chronic thromboembolic pulmonary hypertension: the diagnostic assessment.慢性血栓栓塞性肺动脉高压:诊断评估
Front Cardiovasc Med. 2024 Sep 6;11:1439402. doi: 10.3389/fcvm.2024.1439402. eCollection 2024.
Predictors of Improvement in Exercise Tolerance After Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
球囊肺动脉成形术治疗慢性血栓栓塞性肺动脉高压后运动耐量改善的预测因素。
J Am Heart Assoc. 2023 Feb 7;12(3):e8137. doi: 10.1161/JAHA.122.027395. Epub 2023 Jan 31.
4
A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study.比较慢性血液透析患者使用阿哌沙班与维生素 K 拮抗剂苯丙香豆素的随机对照试验:AXADIA-AFNET 8 研究。
Circulation. 2023 Jan 24;147(4):296-309. doi: 10.1161/CIRCULATIONAHA.122.062779. Epub 2022 Nov 6.
5
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery.ISHLT 共识声明:肺动脉高压和右心衰竭患者手术的围手术期管理。
J Heart Lung Transplant. 2022 Sep;41(9):1135-1194. doi: 10.1016/j.healun.2022.06.013. Epub 2022 Jun 23.
6
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.2022年欧洲心脏病学会/欧洲呼吸学会肺动脉高压诊断和治疗指南。
Eur Respir J. 2023 Jan 6;61(1). doi: 10.1183/13993003.00879-2022. Print 2023 Jan.
7
Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial.球囊肺动脉成形术与 riociguat 治疗不可手术的慢性血栓栓塞性肺动脉高压(MR BPA):一项开放标签、随机对照试验。
Lancet Respir Med. 2022 Oct;10(10):949-960. doi: 10.1016/S2213-2600(22)00171-0. Epub 2022 Aug 1.
8
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.球囊肺动脉成形术与 riociguat 治疗不可手术的慢性血栓栓塞性肺动脉高压(RACE):一项多中心、3 期、开放标签、随机对照临床试验和辅助随访研究。
Lancet Respir Med. 2022 Oct;10(10):961-971. doi: 10.1016/S2213-2600(22)00214-4. Epub 2022 Aug 1.
9
Prognostic implication of noninvasive right ventricle-to-pulmonary artery coupling in chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压中非侵入性右心室-肺动脉耦联的预后意义
Ther Adv Chronic Dis. 2022 Jun 21;13:20406223221102803. doi: 10.1177/20406223221102803. eCollection 2022.
10
Noninvasive follow-up strategy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压肺动脉内膜剥脱术后的无创随访策略
ERJ Open Res. 2022 May 16;8(2). doi: 10.1183/23120541.00564-2021. eCollection 2022 Apr.